Form 4 for ALLO Allogene Therapeutics, Inc.
Accepted 2022-01-14 00:00:00 ET · period of report 2022-01-12 · accession 0001214659-22-000701 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2022-01-14 | 2022-01-12 | ALLO | Belldegrun Arie | Dir | P - Purchase | $12.60 | +155.0K | 195.0K | +388% | +$1.95M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-12 | P | A | 155,039 | $12.60 | 195,039 | I See footnote | — | — | (F1) The reported securities were purchased by Bellco Legacy LLC at an average price of $12.60 per unit, calculated from the price range of $12.35 to $13.00. (F2) The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun. |